AstraZeneca said it plans to pump $2 billion in new investment into the U.S., one of the first major foreign companies to commit significant new spending to the country after Donald Trump’s election win. The decision to go ahead with the spending ...

The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the “important” U.S. market.

AstraZeneca raised its full-year guidance after third-quarter results topped analysts’ expectations, boosted by its cancer and diabetes medicines, and laid out plans for a multibillion-dollar investment in the U.

AstraZeneca Plc raised its annual forecast, driven by strong demand for its blockbuster cancer drugs, and revealed a plan to invest $3.5 billion in the US business by the end of 2026.